Limerick BioPharma raises $1.5M to limit drug side effects
Limerick BioPharma, a South San Francisco firm specializing in drugs that curb the side effects of other drugs, has brought in $1.5 million in debt, rights and securities that it plans to use as working capital, according to VentureWire. Formerly called Limerick Neurosciences, the company says its products minimize the toxic impact some drugs can have on organs that they aren’t targeting — making more medications safer for a wider range of people. So far,… Continue Reading
Limerick BioPharma raises $15.2M for drug bioavailability
A stealthy life sciences startup called Limerick BioPharma has raised $11 million in venture funding and $4.2 million in debt, according to VentureWire. The participants in the round are not clear, but Arch Venture Partners, Sevin Rosen Funds and Altitude Funds are all listed as investors.
Limerick says on its website that it’s working on improving existing therapies through modulating bioavailability — keeping potentially harmful substances out of tissues while maintaining their effectiveness. The technology could… Continue Reading